PetMedix and Zoetis partner to develop species-specific antibody therapies for pets

PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced that it has been acquired by Zoetis, the world’s number one animal health company. Both parties have collaborated since 2022 with respect to antibody discovery. In addition to successful research collaborations, PetMedix’s proprietary drug development activities have led to a promising and large portfolio of antibody drug candidates targeting areas of unmet clinical need in both chronic and terminal diseases affecting dogs and cats. Located at the heart of Europe’s most successful biotechnology cluster, PetMedix will continue operations and act as one of Zoetis’ innovation hubs, providing a centre of research excellence to harness advances in basic and translational research and drive the creation of new treatments for animal disease.

“Today marks a new milestone as PetMedix joins forces with Zoetis, the world’s largest animal health pharmaceutical company. Zoetis is an ideal partner for us, innovation is their number one focus, and this aligns 100% with our approach. Zoetis were the first animal health company to appreciate the power of monoclonal antibody therapy, a technology that was created in Cambridge and has transformed human health. Through their vision and focus on the best science they were the first to launch successful mAb therapeutics to treat chronic diseases in companion animals.

Commercially, Zoetis’ market-leading expertise in developing, manufacturing and commercialising innovative medicines means that PetMedix’s rich portfolio of transformative monoclonal antibodies will achieve regulatory approval in global markets more quickly, and so make a real difference in pet’s lives. That is the whole point of our company, “commented Dr. Tom Weaver, co-founder and CEO of PetMedix. “I couldn’t be prouder of the PetMedix team’s accomplishments. Since our first financing in 2019, our mission has been to elevate expectations in pet care, and we have now taken huge strides towards that goal.”

“As the world leader in animal health, we are always exploring business development and external innovation activities that can complement our internal research and development capabilities,” said Rob Polzer, Executive Vice President and President of Research and Development at Zoetis.

“Adding PetMedix to our R&D organization brings in unique platforms that may accelerate our research and portfolio to potentially help us address our customers’ unmet needs in oncology, inflammatory diseases and other areas, and we are excited about the possibilities ahead.”

Dr. Weaver added, “The acquisition of PetMedix by Zoetis has important implications beyond simply acquiring our technology. The trade sale demonstrates that animal health innovation is alive and well and is an attractive investment opportunity for the venture community, representing a significant RoI. Also, the fact that Zoetis is now joining Europe’s most successful innovation hub means that the UK and Europe will directly benefit from having a welcome injection of investment and expertise in animal health research and development by a proven leader. Together, we intend to advance a “one-health” approach to our research which is so important for both animal and human health alike.”


More news and updates 

Stablepharma secures Innovate UK grant, bridge funding round to launch

This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus and Diphtheria, validating its safety and efficacy through first-in-human clinical trials.

Broken String Biosciences closes $15 million Series A funding round

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design,  has closed a $15 million Series A investment round.

CPI launches RNA Centre of Excellence

UK's first RNA therapeutic innovation center opens in Darlington, driving cutting-edge vaccine and therapeutic development.

UK rare disease research landscape mapped for first time

A detailed view of rare disease research in the UK has been captured for the first time in a new report published today. It reveals over £1.1 billion has been invested by Government and charities over a five-year-period.

Life Science Group: A finalist for the Innovate UK KTP Awards 2023

Life Science Group (LSG) proudly announces its selection as a finalist in the Impact and Transformation Award category of the esteemed 2023 Innovate UK Knowledge Transfer Partnership (KTP) Best of the Best Awards.

Advancing early lung cancer diagnosis

Life Science Group are delighted to be part of a consortium, led by Welsh scientists at Aberystwyth University, to develop a novel and potentially disruptive lateral flow device for the detection of early-stage lung cancer.

Accelerating innovation in cell culture solutions through collaborative funding

Life Science Group Ltd (LSG) is excited to announce that its joint application with the Mary Lyon Centre (MLC) at MRC Harwell to the MRC National Mouse Genetics Network (NMGN) Business Engagement Fund has been approved in principle, pending the signature of the relevant agreements.

FDA grants US Orphan Drug Designation to Medannex's MDX-124

Medannex Ltd announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).

AlveoGene launches to develop inhaled gene therapies for rare respiratory disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)

AstraZeneca commits £100 million to advance UK energy efficiency

15-year agreement with Future Biogas will provide 100 GWh of green gas (biomethane) annually, equivalent to meet the heat demands of over 8,000 homes


More within